Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aptose Bioscns (NQ: APTO )

0.5875 -0.0025 (-0.42%)
Streaming Delayed Price Updated: 12:29 PM EDT, Oct 6, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 26,366
Open 0.5900
Bid (Size) 0.5851 (1)
Ask (Size) 0.5900 (5)
Prev. Close 0.5900
Today's Range 0.5800 - 0.6030
52wk Range 0.5421 - 2.780
Shares Outstanding 92,294,734
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Aptose Biosciences: Q2 Earnings Insights
Aptose Biosciences (NASDAQ:APTO) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:01 PM. Here's what investors need to know about the announcement. 
Via Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga

Performance

YTD
-61.35%
-61.35%
1 Month
-23.70%
-23.70%
3 Month
-28.35%
-28.35%
6 Month
-58.04%
-58.04%
1 Year
-73.65%
-73.65%

More News

Read More
FDA Grants Fast Track designation To Aptose Biosciences for HM43239 in Relapsed/Refractory AML Patients and FLT3 Mutation
Via Benzinga
38 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
32 Stocks Moving in Wednesday's Pre-Market Session
Via Benzinga
Aptose Biosciences: Q4 Earnings Insights
Via Benzinga
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout
Via Benzinga
Earnings Scheduled For March 22, 2022
Via Benzinga
Earnings Preview: Aptose Biosciences
Via Benzinga
Earnings Outlook For Aptose Biosciences
Via Benzinga
Earnings Preview For Aptose Biosciences
Via Benzinga
The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Aptose Shares Fall After Ceasing APTO-253 Program
Via Benzinga
5 Penny Stocks Insiders Are Buying
Via Benzinga
34 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
58 Biggest Movers From Yesterday
Via Benzinga
The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks
Via Benzinga
50 Biggest Movers From Yesterday
Via Benzinga
Aptose Shares Fall After HM43239 Data Featured At ASH Annual Meeting, Luxeptinib, APTO-253 Update
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
20 Stocks Moving in Tuesday's Pre-Market Session
Via Benzinga
The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.